Discure Technologies is an Israeli startup and a medical device company focused on developing innovative solutions for degenerative disc disease (DDD). Their flagship product, the Discure System, is a minimally invasive, implantable bioelectronic device designed to treat and potentially reverse the progression of DDD.
The Company secured $11 million in an oversubscribed Series A financing round, following a SAFE (Simple Agreement for Future Equity) raise of $5 million, bringing the total equity financing it has raised to $16 million. The Series A round was led by BOLD Capital Partners, Supernova Invest and Sanara Capital.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Degenerative disc disease (DDD) is a common condition that occurs when the intervertebral discs, the cushions between the vertebrae in your spine, begin to break down. DDD can be caused by age, trauma and even genetics.
The most common symptom of DDD is often described as a dull ache or sharp pain. If the discs in the cervical spine degenerate, it can lead to neck pain. If the discs in the lumbar spine degenerate and compress the sciatic nerve, it can cause sciatica, characterized by pain that radiates down the leg. Degenerating discs can sometimes lead to numbness or tingling in the arms or legs and in severe cases, DDD can cause muscle weakness.
Unlike traditional treatments that focus on pain management, the Discure System aims to address the underlying cause of DDD by restoring the disc’s natural function. The implantation of the Discure System requires a small incision and can be performed in an outpatient setting, reducing the risk of complications and recovery time compared to open back surgery. Clinical studies have shown that the Discure System can significantly reduce pain, improve function, and reduce the need for opioid medications.
Discure explained that low back pain is the leading cause of disability globally, the second most common reason for physician visits in the U.S., and accounts for economic losses in excess of $100 billion annually in the U.S. alone. DDD is associated with over 35% of all low back pain cases. Current treatments for DDD include opioids, injections and invasive surgery, and are only symptom-modifying with limited long-term relief.
“We welcome our new partners and investors to our existing investor group. The SAFE allowed us to complete development of the Discure System, as well as successfully complete our comprehensive pre-clinical program, adding studies in large animals and human cadaveric discs, thereby setting the stage for this successful Series A round. This latest investment will accelerate our growth, allowing us to make key hires and fully fund our First-in-Human clinical study in Canada and Italy,” said Yuval Mandelbaum, CEO, Discure Technologies. “The investment validates the Company’s novel, minimally invasive approach to reverse disc degeneration, shifting the paradigm from symptom management to addressing the problem by regenerating the disc.”
